ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
twitter youtube facebook linkedin iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home Evolving Standards of Care U.S. Drug Approvals: 2010 – 2020

U.S. Drug Approvals: 2010 – 2020

on: April 16, 2020In: Evolving Standards of Care
Print Email
U.S. Drug Approvals: 2010 - 2020
Share 0
Tweet
Share

Posted: April 16, 2020

ILCN_Migrated_DrugApprovalTimeline
Tags: afatinibalectinibatezolizumabbrigatinibceritinibcrizotinibdabrafenibdacomitinibdecade in reviewdurvalumaberlotinibgefitiniblarotrectiniblorlatinibnecitumumabnivolumabosimertinibpembrolizumabramucirumabtrametinib
Share 0
Tweet
Share

About the authors

Related Articles

  • Pragmatic Approach to Trial Design Born from Lung-MAP Substudy

    Pragmatic Approach to Trial Design Born from Lung-MAP Substudy

    March 21, 2023
  • Narrow Focus Allows Pragmatica-Lung Trial to Minimize Eligibility Criteria, Significantly Reduce Data Collection, Researcher Says

    Narrow Focus Allows Pragmatica-Lung Trial to Minimize Eligibility Criteria, Significantly Reduce Data Collection, Researcher Says

    March 07, 2023
  • CodeBreaK 200 Confirms Sotorasib’s Superiority Compared to Docetaxel, Investigator Says

    CodeBreaK 200 Confirms Sotorasib’s Superiority Compared to Docetaxel, Investigator Says

    February 21, 2023
  • Tobacco Smoking-Related Mutational Signatures: Is it Time to Move on From Patient-Reported History?

    Tobacco Smoking-Related Mutational Signatures: Is it Time to Move on From Patient-Reported History?

    February 21, 2023
IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2023 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy